

## CAR-T Cell Therapy Infectious Disease Prophylaxis Protocol

<b>Antibacterial</b>	<b>Levofloxacin 500mg daily</b> (or renally dosed if CrCl <50) <ul style="list-style-type: none"> <li>Begin when ANC &lt; 500, discontinue when ANC &gt;500</li> </ul>
<b>Antifungal</b>	<b>Fluconazole 400mg daily</b> (or renally dosed if CrCl <50) <ul style="list-style-type: none"> <li>Begin at Day 0, continue through Day +30</li> <li>If prolonged neutropenia &gt; 14 days post-CART or history of mold infection, switch to <b>posaconazole DR 300mg daily</b></li> <li>If CRS (ICANS) &gt;3, strongly consider changing to anti-mold prophylaxis with <b>posaconazole</b></li> </ul>
<b>Antiviral</b>	<b>Valacyclovir 500mg BID or Acyclovir 800 mg PO BID</b> (or renally dosed if CrCl <50) <ul style="list-style-type: none"> <li>starting on Day -5 (with initiation of lymphodepleting chemotherapy) and continue through 6-12mo (as long as CD4 &gt; 200 at that time)</li> </ul>
<b>Pneumocystis</b>	<b>TMP-SMX 1 DS M/W/F</b> or TMP-SMX 1 SS daily <ul style="list-style-type: none"> <li>starting on <u>neutrophil engraftment</u> (typically days +21 to +28) through Day +180 (as long as CD4 &gt; 200 at that time)</li> <li>If unable to tolerate sulfa, <b>Atovaquone 1500mg daily</b> or <b>dapsone 100mg daily</b> (if G6PD normal)</li> </ul>
<b>Hepatitis B<sup>Δ</sup></b> <i>Only for hep B Core Ab +</i>	<b>Tenofovir alafenamide 25mg daily or entecavir 0.5mg daily or lamivudine 100mg daily</b> (or renally dosed for CrCl <50) <ul style="list-style-type: none"> <li>Start at beginning of chemotherapy (D-5), continue through CAR-T therapy and at least 6mos*</li> </ul>

<sup>Δ</sup>limited data available on outcomes among HBV infected patients with cirrhosis who get CAR-T therapy

\*B cell aplasia can be prolonged and there are no data at this time on T cell immune reconstitution after anti-CD19 CAR-T therapy-- therefore would consider continuing antiviral ppx long-term given reported incidence of HBV reactivation in patients who discontinued ppx 1 yr post-CAR-T

### References

- Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. *Blood*, 2018; 131(1): 121-130.
- Lindsay J, The BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematologic malignancy. *Current Opinion Infectious Diseases*, 2019; 32(6): 538-545.
- Mahmoudajafari Z, Hawks KG, Hsieh AA, et al. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States. *Biology of Blood and Marrow Transplantation*, 2019; (25): 26-33.
- Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and cellular therapy. *Biology of Blood and Marrow Transplantation*, 2019; (00): 1-17.
- Strati P, Nastoupil LJ, Fayad LE et al. Safety of CAR T cell therapy in patients with B cell lymphoma and chronic hepatitis B or C virus infection. *Letters to Blood*, 2019; 133(26):2800-2802.
- Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. *Bone Marrow Transplant*. 2022 Oct;57(10):1477-1488. doi: 10.1038/s41409-022-01756-w. Epub 2022 Jul 15. PMID: 35840746; PMCID: PMC9285870.
- Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. *Blood*. 2020 Aug 20;136(8):925-935. doi: 10.1182/blood.2019004000. PMID: 32582924; PMCID: PMC7441168.
- Little JS, Aleissa MM, Beluch K, Gonzalez-Bocco IH, Marty FM, Manne-Goehler J, Koo S, Hammond SP, Jacobson CA. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. *Blood Adv*. 2022 Aug 23;6(16):4821-4830. doi: 10.1182/bloodadvances.2022007474. PMID: 35802461; PMCID: PMC9631654.
- Garner W, Samanta P, Haidar G. Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions. *J Fungi (Basel)*. 2021 Feb 23;7(2):156. doi: 10.3390/jof7020156. PMID: 33672208; PMCID: PMC7927024.